In a regulatory filing earlier, GeoVax disclosed that on April 11, the company received written notification from Advanced Technology International directing the company to stop work on all of the company’s efforts with respect to Project Agreement No. 01; RRPV-24-04-NGVx-006; “NextGen Vaccinations: Phase 2B Clinical Trial Execution: Phase 2b study to evaluate GEO-CM04S1 COVID-19 vaccine” under the Consortium Base Agreement No. 2024-564 with ATI, the Rapid Response Partnership Vehicle’s Consortium Management Firm funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. “The Notice indicated that BARDA decided to terminate the contract for convenience to the government pursuant to the terms of the Project Agreement,” the filing stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOVX:
- GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital
- GeoVax Labs price target lowered to $8.50 from $15 at Alliance Global Partners
- GeoVax Labs Faces Contract Termination for COVID-19 Vaccine
- RFK Jr. vaccine comments bode well for GeoVax, says Roth Capital
- GeoVax Labs Advances Vaccine Trials and Expands Operations